<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1711">
  <stage>Registered</stage>
  <submitdate>11/10/2007</submitdate>
  <approvaldate>11/10/2007</approvaldate>
  <nctid>NCT00543725</nctid>
  <trial_identification>
    <studytitle>TMC278-TiDP6-C215: A Clinical Trial in Treatment Naive HIV-subjects Patients Comparing TMC278 to Efavirenz in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors</studytitle>
    <scientifictitle>A Phase III, Randomized, Double-blind Trial of TMC278 25mg q.d. Versus Efavirenz 600mg q.d. in Combination With a Background Regimen Containing 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Antiretroviral-naive HIV-1 Infected Subjects.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>TMC278-TIDP6-C215</secondaryid>
    <secondaryid>CR002704</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>HIV Infections</healthcondition>
    <healthcondition>HIV-1</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Acquired immune deficiency syndrome (AIDS / HIV)</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - TMC278
Treatment: drugs - efavirenz

Active Comparator: 002 - efavirenz 600 mg tablet once daily for 96 weeks

Experimental: 001 - TMC278 25 mg tablet once daily for 96 weeks


Treatment: drugs: TMC278
25 mg tablet once daily for 96 weeks

Treatment: drugs: efavirenz
600 mg tablet once daily for 96 weeks

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Number of Participants With Virological Response (Intent-to-Treat - Time to Loss of Virologic Response [TLOVR], &lt;50 Copies Per mL) at Week 48 - Virological response is defined as confirmed plasma viral load less than (&lt;) 50 human immunodeficiency virus-1 (HIV-1) (ribonucleic acid [RNA]) copies/milliliter (ml) at Week 48. The TLOVR algorithm was used to derive response. Response needed to be confirmed at 2 consecutive visits and participants who permanently discontinued were considered nonresponders after discontinuation. Resuppression after confirmed virologic failure was considered as failure. Virologic Failure includes participants who were rebounder (confirmed viral load &gt;= 50 copies/ml after being responder) or who were never suppressed (no confirmed viral load &lt;50 copies/ml).</outcome>
      <timepoint>Week 48</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Number of Participants With Virological Response (Intent-to-Treat - Snapshot, &lt;50 Copies Per mL) at Week 48 - The analysis is based on the last observed viral load (VL) data within the Week 48 window. Virologic response is defined as a VL&lt;50 copies/mL (observed case). Missing VL was considered as non-response. Virologic Failure includes subjects who had VL&gt;=50 copies/mL in the Wk 48 window, subjects who discontinued early due to lack or loss of efficacy, subjects who discontinued for reasons other than an adverse event, death or lack or loss of efficacy and at the time of discontinuation had a VL&gt;=50 copies/mL and subjects who had a switch in background regimen that was not permitted by the protocol.</outcome>
      <timepoint>Week 48</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of Participants With Virological Response (Intent-to-Treat - Time to Loss of Virologic Response [TLOVR], &lt;50 Copies Per mL) at Week 96</outcome>
      <timepoint>Week 96</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of Participants With Virological Response (Intent-to-Treat - Snapshot, &lt;50 Copies Per mL) at Week 96</outcome>
      <timepoint>Week 96</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of Participants With Virological Response (Observed, &lt;50 Copies/mL) at Last On-Treatment Visit (Post-Week 96). - Virological response is defined as (observed) plasma viral load less than 50 human immunodeficiency virus-type 1 (HIV-1) ribonucleic acid (RNA) copies per mL at the last on-treatment post-Week 96 visit.</outcome>
      <timepoint>Variable, ranging from 3 months up to maximum 18 months for TMC278 and 12 months for Efavirenz</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of Participants With Virological Response (Intent-to-Treat - Time to Loss of Virologic Response [TLOVR], &lt;400 Copies Per mL) at Week 48 - Virological response is defined as confirmed plasma viral load &lt; 400 HIV-1 (RNA) copies/mL at Week 48. The TLOVR algorithm was used to derive response. Response needed to be confirmed at 2 consecutive visits and participants who permanently discontinued were considered nonresponders after discontinuation. Resuppression after confirmed virologic failure was considered as failure. Virologic Failure includes participants who were rebounder (confirmed viral load &gt;= 400 copies/mL after being responder) or who were never suppressed (no confirmed viral load &lt;400 copies/mL).</outcome>
      <timepoint>Week 48</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of Participants With Virological Response (Intent-to-Treat - Time to Loss of Virologic Response [TLOVR], &lt;400 Copies Per mL) at Week 96 - Virological response is defined as confirmed plasma viral load &lt; 400 HIV-1 (RNA) copies/mL at Week 96. The TLOVR algorithm was used to derive response. Response needed to be confirmed at 2 consecutive visits and participants who permanently discontinued were considered nonresponders after discontinuation. Resuppression after confirmed virologic failure was considered as failure. Virologic Failure includes participants who were rebounder (confirmed viral load &gt;= 400 copies/mL after being responder) or who were never suppressed (no confirmed viral load &lt;400 copies/mL).</outcome>
      <timepoint>Week 96</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mean Change From Baseline to Week 48 and Week 96 in Absolute and Relative CD4+ Cell Counts (Using Imputed Data) - Change from baseline in CD4+ cell count was imputed in case of missing values: in case of premature discontinuation, data were imputed with the baseline value after discontinuation (i.e. change=0, Non-Completer [NC] = Failure); otherwise last observation carried forward was applied.</outcome>
      <timepoint>Baseline, Week 48, and Week 96</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of Participants With Virologic Failure for the Resistance Determinations by Developing Mutations: First Available On-Treatment Genotypic Data After Failure - Virologic failure for the resistance determinations was defined as lack of virologic response (never having had 2 consecutive plasma viral load &lt;50 copies/mL) and plasma viral load increase of &gt;=0.5 log 10 copies/mL above nadir (i.e., never suppressed), or confirmed loss of virologic response (2 consecutive plasma viral load &gt;=50 copies/mL after having had 2 consecutive plasma viral load &lt;50 copies/mL; i.e., rebounder), or discontinued with a last observed on-treatment plasma viral load &gt;=50 copies/mL after having had 2 consecutive plasma viral load &lt;50 copies/mL. For this study, treatment-emergent reverse transcriptase (RT) resistance associated mutations (RAMs) occurring in at least 2 virologic failures (for at least one treatment group) for the following lists are presented: i) Extended list of Non-nucleoside reverse transcriptase inhibitor (NNRTI RAMs) ii) IAS-USA list of Nucleoside/tide reverse transcriptase inhibitor (N[t]RTI RAMs).</outcome>
      <timepoint>Week 96</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Patient with documented HIV-1 infection

          -  Patient has never been treated with a therapeutic HIV vaccine or an ARV drug prior to
             screening

          -  Patient's HIV-1 plasma viral load at screening is &gt; 5,000 HIV-1 RNA copies/mL (assayed
             by RNA PCR standard specimen procedure)

          -  Patient's virus is sensitive to the 2 nucleoside/nucleotide reverse transcriptase
             inhibitors chosen for treatment

          -  Patient agrees not to start ART before the baseline visit

          -  Patient is HLA-B*5701 negative in case abacavir is included in the patient's treatment
             regimen.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>99</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Previous use of ANY ARV drug for ANY length of time

          -  Any documented evidence of NNRTI resistance associated mutations in patient's HIV

          -  Category C AIDS defining illness, except, Stable Kaposi Sarcoma Wasting syndrome if
             not progressive

          -  Pneumocystis carinii pneumonia (PCP) that is considered not cured

          -  Active TB

          -  Allergy or hypersensitivity to study or background ARTs

          -  Specific grade 3 or 4 toxicity

          -  Kidney impairment: calculated creatinine clearance &lt;50 ml/min</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/06/2008</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>680</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/02/2012</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital> - Darlinghurst</hospital>
    <hospital> - Prahran</hospital>
    <hospital> - Surry Hills</hospital>
    <postcode> - Darlinghurst</postcode>
    <postcode> - Prahran</postcode>
    <postcode> - Surry Hills</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>District of Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kentucky</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Antwerpen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Brussels</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Gent</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Leuven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Campinas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Distrito Barao Geraldo-Campina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Pinheiros</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Recife</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Sao Paulo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Alberta</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>British Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Manitoba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Chile</country>
      <state>Providencia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Chile</country>
      <state>Santiago</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Beijing</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Guangzhou</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Shanghai</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Costa Rica</country>
      <state>San Jose</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Clamart</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Le Kremlin Bicetre</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Montpellier</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Essen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Frankfurt</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hamburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hannover</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>KÃ¶ln</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Mannheim</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Chennai</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Nagpur</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Guadalajara N/A</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Mexico City</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Panama</country>
      <state>Panama City N/A</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Panama</country>
      <state>Panama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Portugal</country>
      <state>Porto</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Puerto Rico</country>
      <state>San Juan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Moscow N/A</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Saint-Petersburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Smolensk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Voronezh</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Bloemfontein</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Cape Town</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Dundee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Johannesburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Pretoria N/A</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Westdene Johannesburg Gauteng</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona N/A</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Elche</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Thailand</country>
      <state>Bangkok</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Manchester</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Tibotec Pharmaceuticals, Ireland</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this trial is to compare the effectiveness, safety and tolerability of TMC278
      given at a dose of 25 mg once daily versus efavirenz (EFV) at a dose of 600 mg once daily,
      when combined with a background regimen containing 2 nucleoside/nucleotide reverse
      transcriptase inhibitors ( investigator choice of ABC/3TC, TDF/FTC or AZT/3TC) in HIV-1
      infected patients who have not yet taken any anti-HIV drugs. The following evaluations will
      be done: antiviral activity, immunologic changes, and viral geno-/phenotype evolution,
      relationship of Pharmacokinetics (PK) and PK/Pharmacodynamics and Medical resource
      utilization and treatment adherence.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00543725</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Tibotec Pharmaceuticals, Ireland Clinical Trial</name>
      <address>Tibotec Pharmaceuticals, Ireland</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>